Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2017), held June 3–7 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Associate Editor David H. Ilson, MD, PhD, reviews key presentations on new gastrointestinal cancer treatments. All meeting abstracts can be viewed in the ASCO meeting library).
A plenary session presentation of the IDEA trial by Shi and colleagues (abstract LBA1) released pooled international data from six phase III trials comparing the use of 3 versus 6 months of capecitabine plus oxaliplatin or FOLFOX c…